Introduction
============

More than ten million individuals worldwide are diagnosed with cancer annually, and effective technologies for eradicating tumors are urgently needed. Traditional approaches such as surgery, chemotherapy, radiation therapy, photodynamic therapy (PDT), and hyperthermia have shown great success in widespread clinical and preclinical use. Among those promising approaches, PDT, a noninvasive and site-directed medical technique based on the destruction of tumor tissues by light inducing reactive oxygen species (ROS) generation, has undergone extensive investigations in recent years. In PDT, a photosensitizer (PS) is activated by a specific wavelength of light to generate ROS or free radicals that can react with the local microenvironment, and eventually results in cell death and tissue devastation [@B1],[@B2]. In terms of spatial selectivity in PDT, specific targeting of the PS to the tumor compartment by attaching with various targeting ligands is crucial. Tumor specific accumulation followed by local irradiation facilitates targeted damage to malignant tissue while sparing surrounding healthy tissues [@B3].

To date, the current clinical use of PDT has been limited to superficial layers of tissues, such as in skin cancer, lung cancer, and esophageal cancer that are easily accessible. A major challenge in most traditional PDT is the difficulty in delivering UV or visible light into the subsurface for PS activation. This limits clinical applications of PDT due to the short penetration depth of illumination light, which leads to ineffective treatment of deep-seated tumors [@B4],[@B5]. One auspicious strategy to overcome the limitation of PDT for deep tumor treatment is the development of novel near-infrared (NIR) PSs or using nanoparticles as PS carriers to establish two-photon PDT or upconversion nanoparticle- mediated PDT [@B6]-[@B9], which aims to minimize tissue interference and improve penetration depth. For example, Cheng et al. showed that the mesoporous silica nanoparticles (MSN) co-encapsulated two-photon absorbing dyes and PS enabled high-energy transfer rates for two-photon activated PDT. The two-photon PDT system enhanced the energy transfer rate up to unprecedented 93% to yield efficacy in deep tissue [@B10]. In another study by Chen et al., plasmon-enhanced photoluminescence of GNRs induced by two-photon excitation at NIR wavelength demonstrated the intra-particle energy transfer. This phenomenon induced singlet oxygen generation, which is worthy of studying its potential for development in clinical translation [@B11]. However, even with this advancement, the photon penetration depth can only be increased to a few centimeters into soft tissue [@B12]. Moreover, reduced ^1^O~2~ generation efficiency has been reported by using NIR-activated PSs, and the efficiency of energy transfer from NP toward the PS has usually limited the clinical use of PDT [@B8],[@B13].

Many recent alternative approaches have been developed to improve tissue penetration capability of PDT, including microwave [@B14],[@B15], ultrasound [@B16] and X-ray [@B17]-[@B19]. Among them, X-ray, with the highest penetration depth, was proposed as an energy source to interact with scintillating nanoparticles and then activate PDT, which could be termed as X-ray excited PDT (hereinafter called as X-ray PDT). In a pilot study, Chen et al. developed self-lighting PDT, in which nanoparticles upon exposure to extrinsic X-rays emit luminescence in the visible region of the spectrum, activating the attached PS, and resulting in the efficient generation of ^1^O~2~ [@B20]. Apart from this, the use of photons from Cerenkov radiation (CR) has been emerging as an internal light source to activate PS *in vivo*. Cerenkov luminescence is mainly composed of UV-blue photons, which deliver rapid and localized excitation source for Cerenkov luminescence induced PDT without prolonged radiation exposure to healthy tissue [@B21]. Even though, remarkable results of cancer eradication *in vitro* and *in vivo* have been observed in recent years [@B22]-[@B24], the investigation, evaluation and application of deep PDT for clinical use are still in its infancy. Much room remains for improving the efficiency of X-ray PDT, including photobleaching of organic PSs during X-ray irradiation [@B25], PS loading efficiency for maximized ^1^O~2~ production [@B24],[@B26], matching and fluorescence resonance energy transfer (FRET) efficiency between scintillator and PS [@B27],[@B28], and illumination fluence and fluence rate [@B29],[@B30]. Moreover, the hypoxia microenvironment of tumor, either pre-existing or as a result of oxygen depletion during PDT, can significantly decrease the effectiveness of PDT-induced cell killing [@B8],[@B31],[@B32]. To minimize the hypoxia-limited therapeutic effect in PDT, a circumventive strategy was developed involving a combination of scintillators and inorganic PSs, such as ZnO or TiO~2~. These approaches not only reduced the possibility of PS photodestruction, but also provided a solution to diminish the O~2~-dependence of PDT [@B33]. Furthermore, in the context of cancer therapy, radiation therapy still plays a critical role in the management of more than 50% of cancer cases. The success of radiation therapy also depends on clinical and radiobiological factors. For example, delivering the dose in single or hypofractionated schedule may increase the therapeutic index of treatment compared to conventionally hyperfractionated radiation therapy. However, hyperfractionated radiation therapy could open temporarily closed blood vessels and result in as short-term local reoxygenation and change cellular radiosensitivity during multifraction delivery [@B34]. Therefore, the radiation dose is believed to be a double-edged sword in X-ray PDT.

Herein, we reported the development of silica-coated scintillating Y~2~O~3~:Eu nanoparticles (Y~2~O~3~:Eu\@SiO~2~) that undergo annealing treatment could exhibit not only enhanced photoluminescence efficiency, but also the ability to generate cytotoxic singlet oxygen, superoxide anion and hydroxyl radical upon X-ray irradiation without the incorporation of any additional PS. In this case, the excitation energy is absorbed first by the host lattices, and the electrons (e^-^) of NPs are promoted across the band gap to the conduction band, which creates a hole (h^+^) in the valence band. We observed that ROS generation may result from electrons in the conduction band and holes in the valence band that exhibit high reducing and oxidizing power, respectively. We further implemented a fractionated radiation regimen with Y~2~O~3~:Eu\@SiO~2~ to explore an approach relevant to clinical conventionally fractionated radiation therapy. By comparing radio-sensitive (CAOV3) and radio-resistant (SKOV3) ovarian cancer cells, our established annealing-modulated Y~2~O~3~:Eu\@SiO~2~ could improve the radiotherapy efficacy of CAOV3 cells by means of ROS generation and inducing reoxygenation to overcome tumor hypoxia. Our work demonstrated that the as-synthesized Y~2~O~3~:Eu\@SiO~2~ had potential applications in X-ray PDT with RL-visualized nanodosimetry to overcome the radio-resistant cancers.

Experiment section
==================

Chemicals and materials
-----------------------

Y(NO~3~)~3~, Eu(NO~3~)~3~, urea, tetraethylorthosilicate (TEOS), ammonium hydroxide (30%), and ethanol were purchased from Acros. Diphenolbenzofuran (DPBF), dihydroethidium (DHE), coumarin-3-carboxylic acid (3-CCA), and 5-tertbutoxycarbonyl-5-methyl-1-pyrroline N-oxide (BMPO) were obtained from Sigma Chemical Co. Propidium Iodide (PI) and YO-PRO-1 was purchased from Invitrogen. All chemicals were used as received without further purification.

Synthesis of Y~2~O~3~:Eu\@SiO~2~ nanoparticles
----------------------------------------------

In a typically synthetic procedure via the urea homogeneous precipitation method [@B35], 0.04 mol•L^-1^ Y(NO~3~)~3~·6H~2~O, 0.002 mol•L^-1^ Eu(NO~3~)~3~·6H~2~O, and 2 mol•L^-1^ urea were mixed together, and then aged for 4 h at 85 ºC. Then, the light-white precursors were collected by centrifugation, washed repeatedly with deionized water, and then dried in an oven at 60 ºC. The precursor of Y~2~O~3~:Eu was obtained after drying this product at 80 ºC for 12 h. Coating of SiO~2~ was carried out by hydrolysis of tetraethoxysilane (TEOS) [@B34]. Firstly, 250 mg of Y~2~O~3~:Eu NPs was dispersed in 100 mL ethanol by sonication for 15 min, and then mixed with 1 mL ammonia (25 wt% purity) with vigorous stirring. Then 0.6 mL TEOS was then added dropwise to the solution. After stirring at room temperature for 1.5 h, the resultant products were washed several times with ethanol and water, and the as-synthesized materials were dried at 60 ºC, and then sintered at 800 ºC in air for 4 h.

Characterization
----------------

Particle morphology of Y~2~O~3~:Eu and Y~2~O~3~:Eu\@SiO~2~ samples was characterized via transmission electron microscope (TEM, Hitachi, H-7650 operating at an acceleration voltage of 80 kV). The excitation sources for the X-ray photoluminescence spectra and X-ray excited optical imaging were the intensity modulated radiotherapy system at the University of Chicago. The irradiator was operating in the range from 40 to 225 kV acceleration potential (no Cu filter), 1\~25 mA tube current, and a 15 mm diameter collimator. The emission spectra were recorded using fiber optic cables connected to a fluorescence spectrometer (USB 4000) from Ocean Optics. For the optical imaging, 10 mg of Y~2~O~3~:Eu\@SiO~2~ nanoparticles was packed into a 1.6 mm ID borosilicate glass tube phantom. The phantom was irradiated with the 140 kV / 20.89 mA, a 15 mm diameter collimated X-ray source, and imaging was performed by a Canon 5D Mark II with Canon 35 mm lens, F 1.4 L (stopped down to F 8.0).

Reactive oxygen species (ROS) detection in solution
---------------------------------------------------

For the quantification of ROS, three specific species, i.e., singlet oxygen (^1^O~2~), superoxide anion (O~2~^•-^), and hydroxyl radical (•OH), were chosen for their biological importance. Generation of these species was measured by three kinds of probes, DPBF (absorbance: 402 nm) and 3-CCA (excitation: 395 nm, emission: 450 nm) were dedicated to the quantification of integrated amounts of ^1^O~2~, and •OH, respectively. Both of DHE and BMPO were assigned to the quantification of O~2~^•-^ [@B37]-[@B39]. Two hundred and fifty micrograms of Y~2~O~3~:Eu\@SiO~2~ was suspended with 1 mL PBS for ROS measurement. ROS probe was premixed with Y~2~O~3~:Eu\@SiO~2~ and then diluted by PBS for the designed final concentration. The resulting final concentrations of DPBF, DHE, and 3-CCA were 40 μM, 10 μM and 25 μM, respectively. Solutions were then exposed to X-rays by using a commercial cabinet X-ray system with the standard X-ray tube operated at 150 kV and 15 mA. Singlet oxygen measurements were made by following the loss of UV absorbance of DPBF in the aqueous Y~2~O~3~:Eu\@SiO~2~ solutions. In the DHE measurement, the solution was excited at 465 nm, and its fluorescence intensity at 585 nm was measured. In the BMPO measurement, the characteristic spectrum of BMPO/•OH adduct (a^N^ = 13.56, a^β^~H~ = 12.30, and a^γ^~H~ = 0.66) was measured.

Phantom preparation and calibration curve establishment
-------------------------------------------------------

Intralipid, with a refractive index close to soft tissue and negligible absorption in visible spectral region has been widely used as tissue-mimicking phantom. Intralipid phantoms were prepared according to the literature [@B38]. Briefly, 2.5 g of type A gelatin was added to 50 mL of deionized water, then the mixture was heated to a temperature above the gelatin\'s melting point until the gelatin dissolved completely and the solution turned transparent. Subsequently, 0.5 g of intralipid and various concentrations of Y~2~O~3~:Eu\@SiO~2~ were added into the gelatin-water solution followed by filling cylindrical molds with the final solution, and let the hydrogel solidify at room temperature. For constructing the calibration curve, an imaging system was established; consisting of an X-ray source (RS-2000, Rad Source Co., Ltd) positioned approximately 20 cm above the intralipid phantom, and a CCD camera module placed perpendicularly to the irradiation source and 30 cm away from the phantom. Black curtains were used to darken the imaging space. Acquired X-RL images were further processed using MATLAB.

*In vivo* radioluminescence imaging
-----------------------------------

For RL studies, nude mice were anesthetized with isoflurane (1.5\~2% inhalation), and the SKOV3 human ovarian cells (5 x10^6^ cells in 0.2 mL PBS) were subcutaneously injected into right flanks of the mice. When the tumors reached approximately 500 mm^3^, tumors were intratumoral injected with different concentration of Y~2~O~3~:Eu\@SiO~2~ and imaged after 1 h using the homemade radioluminescence system operating at 160 kVp and 5 mA. At the end of the study when the survived mice were sacrificed, all tumors in each study group were measured by ICP-MS to quantify the concentration of Y~2~O~3~:Eu\@SiO~2~. All mice were anesthetized with an intraperitoneal injection of a ketamine hydrochloride and xylazine cocktail prior to imaging.

Cell culture
------------

SKOV3 (human ovarian cancer) and CAOV3 (human ovarian cancer) cell lines were purchased from American Tissue Culture Collection (ATCC). SKOV3 and CAOV3 cells were cultured in McCoy\'s 5A (Gibco) and DMEM (Gibco), respectively. All cell lines were incubated at 37 °C in a fully humidified atmosphere of 5% CO~2~.

*In vitro* confocal images of cytotoxicity of Y~2~O~3~:Eu\@SiO~2~ and radiotherapy effects
------------------------------------------------------------------------------------------

To determine the *in vitro* radiotherapy effects, SKOV3 and CAOV3 ovarian cancer cells were cultured in McCoy\'s 5A and DMEM medium containing 10% fetal bovine serum (FBS) at 37 °C under 5% CO~2~. Cells were seeded at a density of 3×10^4^ on a 60 mm dish to permit cell attachment. Until 80% cell density, the cells were carefully washed with phosphate-buffered saline (PBS), refreshed with fresh medium containing 50 μg mL^-1^ of Y~2~O~3~:Eu\@SiO~2,~ and then incubated at 37 °C and 5% CO~2~ for 3h or 24 h. After incubation, the cells were rinsed with PBS three times to remove the excess nanoparticles and placed in fresh medium that contained YOPRO-1 and PI dyes. The cell nuclei were stained with 1 μM Hoechst 33342 for 10 min and washed three times with PBS. For cell morphology and fluorescence imaging, YOPRO-1 was excited at 488 nm and monitored using a 525 ± 5 nm bandpass filter, while PI was excited at 535 nm and monitored using a 620 ± 5 nm bandpass filter. Images were collected using a confocal microscope (Zeiss LSM 710).

Cytotoxicity *in vitro*
-----------------------

The cytotoxic effect of the Y~2~O~3~:Eu\@SiO~2~ was determined by a standard MTT assay in 96 well plates. Approximately 5 × 10^3^ cells were placed in each well and cultured at 37 °C with 5% CO~2~. After 24 h of incubation, the media were removed and replaced with fresh medium supplemented with 10% FBS containing Y~2~O~3~:Eu\@SiO~2~ at concentrations ranging from 0 μg mL^-1^ to 100 μg mL^-1^. After 24, the medium containing Y~2~O~3~:Eu\@SiO~2~ was replaced by 180 μL fresh medium, followed by the addition of 20 μL MTT. After 4 h of culturing, the medium was substituted with DMSO (150 μL); the survival rate was evaluated via absorbance measurements at 570 nm.

Clonogenic assay
----------------

Appropriate cell numbers were plated for survival analysis. Culture medium was removed and replaced with nanoparticle-containing culture medium for 24 h at 37 °C. Radiation was delivered in a single dose of 1\~2 Gy over an appropriate field size at 150 keV and 250 keV, respectively. After irradiation, cells were harvested, counted, and seeded on a 100 mm dish. Cell cultures were then incubated for 10-14 days at 37 °C in 5% CO~2~ in air and 95% humidity. Colonies are fixed with glutaraldehyde (6.0% v/v), stained with crystal violet (0.5% w/v), and counted with each experiment performed in quadruplicate.

*In vivo* radiotherapy combined with X-ray activated PDT effect
---------------------------------------------------------------

All experiments that involved animals were performed in accordance with the guide for the care and use of laboratory animals and approved by the Institutional Animal Care and Use Committee of National Health Research Institutes. *In vivo* experiments were conducted using five to six-week-old female nude mice (BioLASCO Taiwan Co., Ltd.). The mice were anesthetized with isoflurane (1.5\~2% inhalation), and the SKOV3 human ovarian cells (5 x10^6^ cells in 0.2 mL PBS) were subcutaneously injected into right flanks of the mice. The tumors were allowed to reach approximately 500 mm^3^ in volume estimated with the formula 1/2 (L × W^2^), where L and W were the length and width, respectively. The mice were randomized to various treatment groups: control (n= 6), Y~2~O~3~:Eu\@SiO~2~ (16 mg/kg, n = 6), radiation (total 8 Gy; four fractions of 2 Gy every day, n = 6), and combination (n=6). In the group of combined treatment, 0.1 mL of 16 mg/kg Y~2~O~3~:Eu\@SiO~2~ solution was administered to each mouse *via* multipoint intratumoral injection. After 1 h post-injection, the tumors in mice were irradiated using an X-ray irradiator (RS-2000, Rad Source Co., Ltd). Tumor volume observations were measured by caliper twice per week. For each group, immunohistochemical analyses were performed on tumors collected 5 d post-injection and end of experiment.

Measurement of oxygen distribution by photoacoustic imaging
-----------------------------------------------------------

To measure the oxygen saturation (sO~2~) inside the SKOV3 solid tumor, the PA C-scan (i.e., two-dimensional scanning) was performed to acquire functional and reference images. Before and after intratumoral administration of 1 mg of Y~2~O~3~:Eu\@SiO~2~ and treated with 8 Gy X-ray (four fractions of 2 Gy every day), sO~2~ around the tumor was measured at the end of radiation therapy by the differential optical absorption of oxygenated, deoxygenated hemoglobin and total hemoglobin at different wavelengths of 850 nm, 750 nm and 800, respectively. To facilitate comparison of sO~2~ patterns at different groups, the regions of interest (ROI) in tumor were employed in the proximity of reagents\' injection site, and identified using ultrasound imaging. Photoacoustic B-scans of the mice generating average oxygenated and deoxygenated hemoglobin signals were analyzed by custom-developed software based on MATLAB® (R2007a, The MathWorks, USA), and sO~2~ is defined as sO~2~ = \[HbO~2~\]/ \[HbO~2~\]+\[Hb\].

Dual-color immunofluorescent analysis of tumors
-----------------------------------------------

The therapeutic effects were determined by active caspase-3 and Annexin V immunostaining. The cryosections of tumor tissue collected from 5 d post-injection (5 μm thick) were washed three times, with PBS for 5 min and fixed with freshly prepared 4% paraformaldehyde in PBS, for 15 min at room temperature. The sections were probed overnight with a polyclonal rabbit anti-mouse active caspase-3 antibody (GeneTex) and rabbit anti-mouse Annexin V (GeneTex) at 4 °C, followed by incubation with peroxidase-conjugated polyclonal goat anti-rabbit antibodies IgG (DyLight488) (GeneTex) and goat anti-rabbit IgG (Alex Fluor594) for 1 h, at room temperature. The sections were counterstained with Hoechst 33342 for 30 min and mounted with glass coverslips. The tissue sections were then analyzed by fluorescence microscopy.

The cryosections of tumor tissue collected from end of experiment (5 μm thick) were fixed with freshly prepared 4% paraformaldehyde in PBS, for 15 min at room temperature and washed 3 times with PBS. The sections were probed overnight with mouse anti-CD31 antibody (GeneTex) and rabbit anti-αSMA antibody (GeneTex) at 4 °C, followed by incubation with polyclonal goat anti-mouse IgG (DyLight488) antibodies and polyclonal goat anti-rabbit IgG (DyLight594) antibodies (GeneTex) for 1 hour, at room temperature. The sections were counterstained with Hoechst 33342 for 30 min and mounted with glass coverslips. The tissue sections were then analyzed by fluorescence microscopy and quantified by ImageJ software.

Results and discussion
======================

The low-temperature reflux method, utilizing urea-assisted precipitation, was employed to systematically synthesize nanocrystal compositions. The morphology of calcined Y~2~O~3~:Eu was characterized by TEM and is shown **Figure [1](#F1){ref-type="fig"}A**. From the image, it can be observed that the naked Y~2~O~3~:Eu nanoparticles appeared as homogeneous and monodisperse nanospheres with an average size of 160 nm. For biological applications, water solubility is critical. Coating Y~2~O~3~:Eu with SiO~2~ is the most popular strategy to increase the water solubility of nanoparticles. Additionally, since the induced luminescence could be quenched by water and organic molecules *via* a mechanism similar to fluorescence resonance energy transfer (FRET), SiO~2~ could decrease non-radiative transition to prevents the quenching of luminescence quenching [@B41],[@B42]. Therefore, the Y~2~O~3~:Eu nanoparticles were coated with a thin layer of silica using the modified Stöber method and the core-shell structure for the Y~2~O~3~:Eu\@SiO~2~ can be clearly seen due to the different electron penetrability for the cores and shells (as shown in **Figure [1](#F1){ref-type="fig"}B**). The Y~2~O~3~:Eu cores are black spheres with an average size of 160 nm, and the shells have a gray color with an average thickness of 9 nm. It was reported by Liu and colleagues that silica-based nanoparticles with size between 100 and 200 nm own the best efficiencies of the cellular uptake and endosomal escape [@B43],[@B44]. In addition, the coating thickness of outer silica layer has some effect on ROS generation. Due to the extremely short lifespan and severely limited diffusion distance (\< 20 nm), ROS only acts in its immediate vicinity. To strike the balance between ROS generation and biocompatibility, a thin silica-layer (\<10 nm) was used in our study. **Figure [1](#F1){ref-type="fig"}C** shows the EDX spectra of Y~2~O~3~:Eu\@SiO~2~. It is explicitly shown from **Figure [1](#F1){ref-type="fig"}C** that Y, Eu, and Si peaks are at normal energies, which indicates that the composition of coated layer is SiO~2~. The TEM and EDS results as described above confirm the uniform coating of silica shell on our synthesized Y~2~O~3~:Eu\@SiO~2~ nanoparticles. Following synthesis, the optical properties of Y~2~O~3~:Eu\@SiO~2~ nanoparticles were thoroughly characterized. A typical RL spectrum of an aqueous suspension of Y~2~O~3~:Eu\@SiO~2~ nanoparticles under X-ray irradiation is shown in **Figure [1](#F1){ref-type="fig"}D**. The complete RL spectra were collected and subsequently curve-fitted (Gaussian), and exhibited the characteristic luminescence bands at 590 nm, 610 nm, and 627 nm, which can be assigned to ^5^D~0~ → ^7^F~1~, ^5^D~0~ → ^7^F~2~, and ^5^D~0~ → ^7^F~3~ transitions of the Eu^3+^ ion, respectively, indicating that Eu^3+^ sites act as luminescence centers. Based upon the findings in the extant literature, the spectral properties of our RL spectrum of Y~2~O~3~:Eu\@SiO~2~ nanoparticles appear essentially similar to those that were recorded under either UV excitation or X-ray irradiation [@B45],[@B46].

We have compared photoluminescence and ROS generation efficiency between annealed and pre-annealed nanoparticles. Both photoluminescence and ROS generation of pre-annealed Y~2~O~3~:Eu nanoparticles are significantly weaker than those of annealed Y~2~O~3~:Eu nanoparticles (data no shown), the results are in consistent with previous reports. The precursor (Y(OH)CO~3~·H~2~O):Eu^3+^ nanoparticles contains many hydroxyl groups and is either amorphous or paracrystalline. Due to the defects produced during the preparation process and impurities contained in the raw materials, the samples inevitably have quenching centers (traps), which induce non-radiative transitions and decrease the photoluminescence and ROS generation efficiency. Therefore, a calcination process is indispensable for dehydroxylation and crystallization [@B47]-[@B49]. We next investigated X-RL imaging and radio-sensitization of different Eu doping concentrations to determine if there is an Eu-dependent effect. First, the dependence of RL intensity from Eu^3+^ content was measured, as showed in **Figure [2](#F2){ref-type="fig"}A**. It is observed that the relative intensity of 610 nm X-RL first increased up to 2 mol% of Eu^3+^ concentration, and then decreased while Eu^3+^ dopant concentration continuously increased. This decrease of X-RL as the doping Eu^3+^ level higher than 2 mol % should be resulting from the concentration dependent quenching caused by the cross-relaxation between neighboring Eu^3+^ ions [@B50],[@B51]. Thus, the optimal concentration of Eu^3+^ ions in our prepared Y~2~O~3~:Eu\@SiO~2~ is 2 mol% at the time of synthesis. Scintillators are generally capable of converting high-energy X-rays and gamma rays into UV-visible lights. Limited investigations exist on ROS generation from scintillators. In the case of X-ray inducible PDT, energy transfer may occur if a significant overlap exists between the emission of the donor and the absorption of the acceptor. In order to elucidate the ROS generation mechanism in our study, the contribution of Eu^3+^ concentration to the enhanced generation of hydroxyl radical under X-ray irradiation was estimated by electron paramagnetic resonance (EPR) spectrum (**Figure [2](#F2){ref-type="fig"}B**). In the case in which Y~2~O~3~:Eu\@SiO~2~ was mixed with BMPO under X-ray irradiation, the EPR revealed a four-line spectrum which implied an BMPO-OH adduct [@B52]. It is worth noting that as shown in **Figure [2](#F2){ref-type="fig"}C**, the intensities of O~2~^•-^/•OH EPR signals for the as-prepared particles with various Eu^3+^ doping concentrations showed no significant difference. Thus, we do not expect a dominant contribution of Eu^3+^ ions to the ROS generation process under X-ray excitation. At the same time, the RL of Y~2~O~3~:Eu\@SiO~2~ was also observed in the absence of O~2~, as shown in **Figure [2](#F2){ref-type="fig"}D**. Moreover, no significant RL variation was found between the normal and O~2~ ablation conditions, which indicated that implied RL in our established system is an O~2~- systems, and thus Y~2~O~3~:Eu\@SiO~2~ could be employed in image-guided radiotherapy.

PDT allows the destruction of tumors by generating more reactive oxygen species, most often by the singlet oxygen via type II reaction. Herein, the contribution of Y~2~O~3~:Eu\@SiO~2~ to the enhanced generation of singlet oxygen production under X-ray irradiation was quantified by measuring the decrease in the optical absorption at 420 nm of Y~2~O~3~:Eu\@SiO~2~ nanoparticles suspended in DPBF. **Figure [3](#F3){ref-type="fig"}A** illustrates the photobleaching of DPBF in H~2~O in the presence of Y~2~O~3~:Eu\@SiO~2~ nanoparticles as a function of X-ray dose, relative to a pristine DPBF control (nanoparticle-free) solution. The decrease of DPBF absorption with X-ray dose in the Y~2~O~3~:Eu\@SiO~2~ nanoparticle suspension reflects the efficient generation of highly reactive ^1^O~2~. Recently, some groups reported that silica coating enhanced luminescent intensity and suspensibility of Eu-doping phosphor [@B53]-[@B55]. However, with a thick silica layer, the efficiency of the radio-sensitizer may be reduced because it is difficult for reactive singlet oxygen species to diffuse out of the silica layer [@B56]. In our study, the result demonstrated that there was no obvious effect in the sensitization enhancement under thin silica coating.

Besides singlet oxygen, other biologically important reactive oxygen species (ROS), such as •OH and O~2~^•-^, were also characterized during the X-ray excitation of Y~2~O~3~:Eu\@SiO~2~ nanoparticles. The DHE is highly sensitive to O~2~^•-^ and responses increased as the X-ray absorbed energy. As shown in **Figure [3](#F3){ref-type="fig"}B**, only Y~2~O~3~:Eu\@SiO~2~ yielded a considerable amount of O~2~^•-^ under X-ray irradiation. Furthermore, we employed 3-CCA as a trapper to determine whether hydroxyl radical generation can be enhanced by irradiated Y~2~O~3~:Eu\@SiO~2~. From the result shown in **Figure [3](#F3){ref-type="fig"}C**, one can clearly observe the enhanced generation of •OH that arises from the presence of Y~2~O~3~:Eu\@SiO~2~ nanoparticles as a function X-ray irradiation dose. Furthermore, it was statistically determined that the ^1^O~2~, O~2~^•-^, and •OH generations were enhanced by 8.0, 5.4 and 1.6-fold, respectively, in use of Y~2~O~3~:Eu\@SiO~2~ mediated X-ray PDT.

In previous investigations, metallic materials with a high atomic number (Z), such as gold nanoparticles have been demonstrated to enhance photoelectric and Compton effects (and thus the subsequent emissions of secondary electrons) to augment radiation therapy efficacy. However, there are only limited investigations on ROS generation from scintillators. Y~2~O~3~ was shown to be an effective scintillator that procures self-trapped excitons at defect sites within the bulk matrix under X-ray irradiation. The incident X-ray photons promote electronic transitions from the valence band to the conduction band and create holes (h^+^) with oxidizing power in the valence band, and electrons (e^-^) with reducing power in the conduction band, respectively [@B57],[@B58]. In this work, the contribution of annealing-treated Y~2~O~3~:Eu\@SiO~2~ to the enhanced generation of a specific type of ROS (e.g., •OH, O~2~^•-^ and ^1^O~2~) could be related to the electronic structures of the Y~2~O~3~:Eu\@SiO~2~ nanoparticles, as well as the redox potentials (E~H~) of the different ROS generation reactions. Specifically, upon X-ray illumination, a part of energy could transfer from Y~2~O~3~ nanoscintillators to the Eu^3+^ optical center for fluorescence emission; another part of X-ray energy would be imparted to generate electron-hole pairs (**Scheme [1](#SC1){ref-type="fig"}**). The photoexcited electrons and holes then react with an aqueous electron acceptor (i.e., molecular oxygen) and donor (i.e., water and hydroxyl ions), respectively, to produce different types of ROS. In a previous study, Li and coworkers reported that ROS generation reactions are thermodynamically favorable and predictable by aligning valance band (Ev), conduction band (Ec), and E~H,~ and vice versa [@B59]. As has been demonstrated in previous research, the band gap of Y~2~O~3~ is 5.6 eV, and the theoretical Ev and Ec were 5.25 eV and -0.35 eV, respectively [@B60]. As shown in **Figure [3](#F3){ref-type="fig"}**, our experimental results indicated that Y~2~O~3~:Eu\@SiO~2~ generated more O~2~^•-^ than the control alone. This suggests that, since the Ec value of Y~2~O~3~ (-0.35 eV) is lower than the E~H~ of O~2~/ O~2~^•-^ (-0.2 eV), electrons could transfer from Y~2~O~3~ to O~2~ and drive superoxide anion generation. Similarly, the E~H~ for •OH and ^1^O~2~/O~2~ generation is approximately 2.2 eV and 1.8 eV, respectively. This means that the holes of Y~2~O~3~ (Ev = 5.25 eV) could theoretically oxidize H~2~O into •OH, and drive ^1^O~2~ production in Y~2~O~3~ solution. It is noteworthy that, unlike conventional PDT that is dependent on the availability of oxygen concentration for Type II reaction, our established PDT effect comprises both Type II energy transfer (oxygen-dependent) and Type I redox reactions (oxygen-independent), and thus minimizes the impediment imposed by the tumor hypoxia on PDT. To further evidence this claim and investigate forms of induced ROS, Y~2~O~3~:Eu\@SiO~2~ responses to the absence of O~2~ gas were monitored using different indicators for specific ROS inductions following X-ray irradiation. As shown in **Figure [3](#F3){ref-type="fig"}D**, a pronounced decrease of singlet oxygen was observed after O~2~ deprivation under ambient temperature. By contrast, no significant reductions were found in hydroxyl radical and superoxide anion generations in the absence of O~2~. Given the observations, Y~2~O~3~:Eu\@SiO~2~ produces comprehensive X-ray activated photodynamic reactions that encompass ^1^O~2~, hydroxyl radical, and superoxide anion, implicating its highly potential utility in PDT for hypoxic cancers.

In order to investigate the use of Y~2~O~3~:Eu\@SiO~2~ for biomedical X-ray excited optical luminescence (XEOL) imaging applications, a cabinet irradiator unit was outfitted with a detector positioned perpendicular to a light-tight imaging space (**Figure [4](#F4){ref-type="fig"}A**). To determine the temporal resolution of the X-RL imaging system, RL from 0.1 to 3 mg of Y~2~O~3~:Eu\@SiO~2~ in 10% gelatin with 1% intralipid phantom were captured under various detector exposures following X-ray irradiation (**Figure [4](#F4){ref-type="fig"}B**). Next, to confirm the practical application of X-RL of Y~2~O~3~:Eu\@SiO~2~, various concentrations of Y~2~O~3~:Eu\@SiO~2~ were i.t injected into the back flanks tumor of the mice. Anesthetized mice were imaged over 10 s using our custom X-RL imaging system operating under 160 kVp and 5 mA. RL emissions from the 1 mg Y~2~O~3~:Eu\@SiO~2~ inclusion were clearly detectable from the injection site (**Figure [4](#F4){ref-type="fig"}C**). In order to test the feasibility of our proposed method in real samples, the mice were sacrificed, and the unknown concentrations of Y~2~O~3~:Eu\@SiO~2~ in different tumors were analyzed using ICP-MS. The analytical results are shown in **Table [1](#T1){ref-type="table"}**. The results obtained with X-RL imaging were in good agreement with those obtained by using the ICP-MS method, with a relative error of less than 10%, except 1 mg of Y~2~O~3~:Eu\@SiO~2~. These results demonstrate that our proposed method in this work is applicable for real-time detection in *in vivo* study. As shown in**Figure [3](#F3){ref-type="fig"}**, we have demonstrated that the ability of ROS generation of Y~2~O~3~:Eu\@SiO~2~ is independent of europium dopant ion concentration. In addition, in consideration of lanthanide ions are close in ionic radius to yttrium (for example, 1.933 A° for Yb, 1.761 A° for Er and 1.8 A° for Y), the lanthanide ions could be incorporated into the Y~2~O~3~ host without significant lattice distortions. It implicated that we could replace europium with other rare-earth elements (such as Yb^3+^ and Er^3+^), so to shift the corresponding radioluminescences toward longer wavelengths for better tissue penetration.

Prior to any biological application, the cytotoxicity of the as-prepared Y~2~O~3~:Eu\@SiO~2~ was first assessed by an MTT assay. Different concentrations of Y~2~O~3~:Eu\@SiO~2~ were incubated with either CAOV3 or SKOV3 cells for 24 h in cell culture medium. As shown in **[Figure S1](#SM0){ref-type="supplementary-material"}**, at a concentration as high as 100 μg mL^-1^, the cell viability of both CAOV3 and SKOV3 still remained above 90% after 24 h incubation with Y~2~O~3~:Eu\@SiO~2~, demonstrating the excellent biological compatibility of Y~2~O~3~:Eu\@SiO~2~. As mentioned above, we have demonstrated that the X-ray irradiation of annealing-treated Y~2~O~3~:Eu\@SiO~2~ nanoparticles generated ROS *via* comprehensive photodynamic effects (both Type I and II). Consequently, we evaluated if the ability of the as-synthesized Y~2~O~3~:Eu\@SiO~2~ to generate ROS and induce cell damage after exposure to X-ray radiation which using both radio-sensitive (CAOV3) and radio-resistant (SKOV3) cell lines. As shown in **Figure [5](#F5){ref-type="fig"}**, untreated and Y~2~O~3~:Eu\@SiO~2~ treated CAOV3 cells exhibited negligible change in cell viability. Under X-ray irradiation, cells showed positive for PI staining within 3 h, as an indication of cell death, and the number of viable cells decreased after 24 h incubation. In contrast with CAOV3 cells, SKOV3 cells exhibited negligible change in cell viability in untreated, Y~2~O~3~:Eu\@SiO~2~, and X-ray alone groups. We postulate that these finding reflect that the radio-resistant SKOV3 cells eliminated the ROS by its intracellular repair capability [@B61]. The combined treatment showed cells with a positive signal for YO-PRO-1 at the initial phase (3 h), indicating changes in plasma membrane permeability. At the late phase (24 h), the majority of cells were positive for PI staining. These results demonstrated that our Y~2~O~3~:Eu\@SiO~2~ overcame the resistance of SKOV3 cells.

The destruction of tumor cells following X-ray irradiation of Y~2~O~3~:Eu\@SiO~2~ nanoparticles was determined by clonogenic assay, i.e., based upon the ability of a single cell to grow, post-treatment, into a colony. As shown in **Figure [6](#F6){ref-type="fig"}**, significant killing of both SKOV3 and CAOV3 cells was observed in the presence of Y~2~O~3~:Eu\@SiO~2~ nanoparticles with both 150 keV and 250 keV X-ray, and considerably more than with radiation alone. For the radiation-sensitive CAOV3 cells, the nanoparticles enhanced the therapeutic effect up to 40% in the 2 Gy of 150 keV X-ray. Most importantly, in the radio-resistant SKOV3 cells, more than 50% cell death was shown with Y~2~O~3~:Eu\@SiO~2~ nanoparticles at 2 Gy of 150 keV X-ray irradiation. The Y~2~O~3~:Eu\@SiO~2~ nanoparticles demonstrated significant therapeutic potential with lower dosage and energy X-ray irradiation in both radio-sensitive and resistant ovarian cancer cells.

Ovary is a radiosensitive tissue, and damage to ovary is of profound importance owing to the lack of repair of normal tissue and potentially severe sequelae. Because ovarian cancer is rarely confined to the pelvis, whole abdominal radiotherapy (WAR) was used to sterilize large volumes of micrometastatic intraperitoneal disease. Limited tolerance of the bowel, kidneys and liver also reduces the amount of radiation. Therefore, low-dose hyperfractionation could be considered as part of the standard management for ovarian cancer [@B62]-[@B65]. Encouraged by the *in vitro* results, we further investigated an approach that is relevant to clinical stereotactic body radiation therapy: combination of radio-sensitization enhancement with a fractionated radiation regimen. Radiation was administered in four fractions of 8 Gy every other day (q1d×4) (**Figure [7](#F7){ref-type="fig"}A**). The effects of various treatments on the growth of subcutaneous SKOV3 tumors are shown in**Figure [7](#F7){ref-type="fig"}B**. The tumors in the control group progressively increased in size, which enlarged nearly by four-fold in tumor volume within 14 d. Compared with the aggravating increase tendency in the control group, either Y~2~O~3~:Eu\@SiO~2~ or X-ray radiation alone caused visible tumor growth delay within the first 4 d, accompanied by an approximately 25% and 50% tumor volume decrease at the end of 14 d, respectively. In the combination regimen, the tumor growth inhibition was enhanced; resulting in tumor growth stasis during the period of 25 d. Overall, tumor volume was delayed by five-fold compared to the control (474 mm^3^ vs. 2371 mm^3^). After 24 d, five of the six mice treated with Y~2~O~3~:Eu\@SiO~2~ and X-ray survived. The survival rates in those treated with X-ray alone, Y~2~O~3~:Eu\@SiO~2~ alone and control group were 66%, 0%, and 0%, respectively. (**Figure [7](#F7){ref-type="fig"}C**). No obvious toxicity was observed in the mice following Y~2~O~3~:Eu\@SiO~2~ administration, such as sudden death, abnormal behavior, significant changes of food in body weight. In addition, the histopathology examination confirmed that the structural patterns of major organs, including heart, liver, spleen, lung and kidney, of both the Y~2~O~3~:Eu\@SiO~2~ combined with X-ray irradiation group and X-ray alone group are similar to those of the control group. These results suggest that no obvious acute toxicity reaction was induced in the treatments (**[Figure S2](#SM0){ref-type="supplementary-material"}**).

It is well known that the response of tumor cells to radiation is closely related to oxygen supply through blood perfusion, and that fractionated radiotherapy minimizes radiation-induced vascular damage, thereby allowing reoxygenation of hypoxic tumor cells. To evaluate the contribution of Y~2~O~3~:Eu\@SiO~2~ presence to radiation dose enhancement and reoxygenation, photoacoustic imaging (PAI) was performed to discern oxygen saturation (~S~O~2~) from the oxygenated and deoxygenated hemoglobin at different wavelengths of 850 and 750 nm, respectively [@B66]-[@B68]. As seen in **Figure [8](#F8){ref-type="fig"}A**, the PAIs did not show any observable changes between the control and Y~2~O~3~:Eu\@SiO~2~ alone group. Furthermore, we noticed an unusual ~S~O~2~ decrease was found in the X-ray alone group after the treatment process. Surprisingly, the PAI in the combined group exhibited an observable increase in the ~S~O~2~. This is of particular interest when considering potential applications of Y~2~O~3~:Eu\@SiO~2~ in X-ray PDT. Through measurement of ~S~O~2~ levels, the relative mean ~S~O~2~ showed a slight difference between the X-ray and the combined group (**Figure [8](#F8){ref-type="fig"}B**). Furthermore, the normalized ~s~O~2~ at the periphery of Y~2~O~3~:Eu\@SiO~2~ were obtained and quantified. It was found that the tumor treated with X-ray leads to a decrease of the ~S~O~2~ distribution (~s~O~2~ was 50% at ~s~O~2\ 0\~15%~ and 50% at ~s~O~2\ 15\~30%~), when compared to the control (~s~O~2~ was 33.3% at ~s~O~2\ 15\~30%~ and 66.7% at ~s~O~2\ 30\~45%~) and the Y~2~O~3~:Eu\@SiO~2~ alone groups (~s~O~2~ was 33.3% at ~s~O~2\ 15\~30%~, 50% at ~s~O~2\ 30\~45%~ and 16.7% at ~s~O~2\ ≥45%~) (**Figure [8](#F8){ref-type="fig"}C**). This phenomenon is in agreement with the extant literature [@B69], and is ascribed to endothelial death (with a threshold dose of 5\~10 Gy) and a decrease in oxygen supply after X-ray irradiation. Moreover, Hasan et al. reported that PDT, as well as high single-dose radiation therapy, can create a temporal hypoxia region in tissue adjacent to perfused blood vessel [@B70]. This event might be expected to attenuate radiation therapy response. Additionally, an inadequate supply of O~2~ (hypoxia) has long been recognized as a cause of radio-resistance, in which hypoxic tumor cells are approximately three times more resistant to radiotherapy (known as \'\'the oxygen effect"). Interestingly, the Y~2~O~3~:Eu\@SiO~2~ with X-ray group showed enhanced ~s~O~2~ level at the periphery of tumor administered with Y~2~O~3~:Eu\@SiO~2~ (~s~O~2~ was 33.3% at ~s~O~2\ 0\~15%~, 33.3% at ~s~O~2~ 15\~30%, 8.4% at ~s~O~2\ 30\~40%~ and 25% at ~s~O~2\ ≥45%~). It could be reasonably speculate that, upon X-ray PDT, the oxygen demand in tumors is drastically diminished due to severe damage to tumor cells. On the other hand, the oxygen supply through blood perfusion continuously contributes to the intratumoral oxygen tension. Potiron et al. demonstrated that fractionated radiotherapy increased intratumoral doxorubicin diffusion [@B71]. These results are in accordance with Hansen et al., who reported that tumors displayed an increased mean accumulation of liposomes for radiation doses up to 10 Gy [@B72]. We observed obvious difference between the ~s~O~2~ values of the X-ray alone and the combined groups at 1 h post-X-ray PDT.

Induction of apoptosis in SKOV3 tumors at the end after various treatments is depicted in **Figure [9](#F9){ref-type="fig"}A**. As illustrated in **Figure [9](#F9){ref-type="fig"}A**, tumors treated with X-ray combined with Y~2~O~3~:Eu\@SiO~2~ showed the highest Annexin V expression, an early apoptosis marker, as compared to tumors with only X-ray irradiation and with Y~2~O~3~:Eu\@SiO~2~ alone. Moreover, the strongest caspase 3 signal was also observed in the group of X-ray combined with Y~2~O~3~:Eu\@SiO~2~, suggesting that Y~2~O~3~:Eu\@SiO~2~ effectively enhanced radiotherapy *via* cell apoptotic cascade. To explore other possible mechanisms besides apoptosis that synergistically contributed to the enhanced inhibition of tumor growth in the presence of our annealed Y~2~O~3~:Eu\@SiO~2~, we further assessed tumors harvested from various groups with immunofluorescence (IF) imaging of CD-31. The IF images showed a decrease in CD-31 positive endothelial cells at the end of treatment compared to the other groups (**Figure [9](#F9){ref-type="fig"}B**). Consistent with previous reports, high doses of radiation induced additional tumor cell killing through "non-classical" radiobiological mechanisms, mediated by tumor microvascular damage [@B73]-[@B75]. Specifically, Demidov et al. carried out longitudinal*in vivo* imaging observations, and demonstrated that maximal tumor shrinkage increases with dose, and the time to initial vascular volume density recovery is also dose-dependent. In our study, ~s~O~2~ in the combined group increases rapidly after irradiation, probably due to damage in the endothelial cells followed by widening of the gaps between endothelial cells. However, we also observed the vascular volume density declined at the end of treatment in combined group. Wang and colleagues reported copper-cysteamine NPs-mediated X-PDT, which caused a decrease in the number of vessels, but did not inhibit the growth of radio-resistant melanoma [@B76]. In our study, we demonstrated NP-mediated X-ray PDT combined with fractionated radiation therapy, which decreased the tumor vessels at the end of *in vivo* study. Further, multi-shots X-ray PDT treatment improved oxygen distribution at the periphery of tumor administered with Y~2~O~3~:Eu\@SiO~2~, and enhanced efficiency of X-ray to inhibit the growth of radio-resistant SKOV3. To further validate and assessed these findings, CD-31 and α-smooth muscle actin (α-SMA) stain was utilized to depict the vascular remodeling and pericyte recruitment. As shown in **Figure [9](#F9){ref-type="fig"}C**, a decrease in CD-31 (64%) intensity was found at the end of treatment compared to non-irradiated and NP alone tumors. Interestingly, in the X-ray alone group, an increase in α-SMA intensity was observed after three weeks of RT compared to non-irradiated (2.3-fold), NP alone (1.4-fold), and NPs combined with X-ray irradiated tumors (2.4-fold), indicating that the sublethal dose of irradiation could enhance radiotherapy-induced vascular remodeling at the late stage (**Figure [9](#F9){ref-type="fig"}D**). The X-ray induced vascular remodeling indexed with α-SMA was compromised in combined group is probably ascribed to the ROS generated by the annealed Y~2~O~3~:Eu\@SiO~2~ following X-ray irradiation, where the photoexcited electrons and holes of Y~2~O~3~ react with an aqueous electron acceptor (i.e., molecular oxygen) and donor (i.e., water and hydroxyl ions) to produce different types of ROS that abolish pericyte recruitment. Together, these findings implicate that annealed Y~2~O~3~:Eu\@SiO~2~ combined with fractionated radiation therapy has the potential to be utilized to reverse vascular remodeling-enhanced tumor resistance to radiation therapy.

Conclusion
==========

In summary, we have developed Y~2~O~3~:Eu\@SiO~2~ nanoscintillators that could be potentially used for X-RL imaging-guided radiotherapy with a significant radio-sensitization enhancement. It is notable that the annealing pretreatment is critical for Y~2~O~3~:Eu\@SiO~2~ to render such a PS-independent radio-sensitization enhancement that comprises comprehensive photodynamic effects and pronounced RL for possible imaging guidance and *in-situ* dosimetry assessment. This report further demonstrated that RL emission and ROS generation constitute two parallel and independent mechanisms, which is important as it implicates that the Y~2~O~3~:Eu\@SiO~2~ could harness the ionizing radiation efficiently to reach the maximal theranostic utilization. In imaging, the red-emitted X-RL of Y~2~O~3~:Eu\@SiO~2~ was quantitatively monitored for nanoparticle tumor accumulation and dosimeter assessment *in vivo*. However, in consideration of the penetration depth and scattering attribute of red X-RL in tissue, the quantitative dosimetry and imaging of Y~2~O~3~:Eu\@SiO~2~ are constrained to superficial tumors. We have demonstrated the ability of ROS generation of Y~2~O~3~:Eu\@SiO~2~ is independent of europium dopant ion concentration. Furthermore, due to the similar ionic radius of lanthanide ions to yttrium (for example, 1.933 A° for Yb, 1.761 A° for Er and 1.8 A° for Y), the challenge of producing high-penetration X-RL in our nanotheranostics may be addressed by substituting Eu^3+^ with other rare-earth-ions such as Yb^3+^ and Er^3+^ in the doping process, to possibly tuning and extending the peak emission wavelengths to near infrared I and II regions. In addition, the generation of electron-hole pairs in Y~2~O~3~ could react with an aqueous electron acceptor (i.e., molecular oxygen) and donor (i.e., water and hydroxyl ions), which essentially minimize oxygen dependency for the generation of reactive oxygen species. Furthermore, for the *in-vivo* radio-sensitizing effect of our established nanoparticles, the preliminary results from tumor xenografts suggested that the therapeutic enhancement observed *in vivo* by Y~2~O~3~:Eu\@SiO~2~-derived radio-sensitization could be readily translated to favorable radiotherapy for tumor control. A new indication is noteworthy that Y~2~O~3~:Eu\@SiO~2~ in combination with fractionated radiation therapy could induce vascular remodeling that accompanied by decreased hypoxia distribution intratumorally. It is anticipated to alleviate the radiobiological effect associated with tumor radioresistance and to substantially improve conventional PDT.
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![**Characterization of Y~2~O~3~:Eu\@SiO~2~. TEM images of** (A) Y~2~O~3~:Eu and (B) Y~2~O~3~:Eu\@SiO~2~; (C) EDX analysis of Y~2~O~3~:Eu\@SiO~2~ particles, and (D) Typical radioluminescence spectra showing dominant emission peaks at 590, 610 nm, and 627 nm, as well as their corresponding, independent Gaussian curve-fits.](thnov10p6758g001){#F1}

![**RL and O~2~^•-^/•OH generation variation at different conditions**. (A) Emission spectrum Y~2~O~3~:Eu\@SiO~2~ with different Eu^3+^; (B) concentration demonstration of superoxide anion/hydroxyl radical enhanced by Y~2~O~3~:Eu\@SiO~2~ under ionizing irradiation; (C) Relative ESR intensity Y~2~O~3~:Eu\@SiO~2~ with different Eu^3+^ concentration. (D) Emission spectra of Y~2~O~3~:Eu\@SiO~2~ nanoparticle before (black) and after bubbling N~2~ gas (red).](thnov10p6758g002){#F2}

![**ROS generation kinetics of Y~2~O~3~:Eu\@SiO~2~ as a function of X-ray absorbed energy.** (A) ^1^O~2~ measured by DPBF; (B) O~2~^•-^ measured by DHE; and (C) •OH measured by 3-CCA. (D) ROS generation of Y~2~O~3~:Eu\@SiO~2~ before (light grey) and after bubbling N~2~ gas (dark grey) with 10 Gy X-ray. The samples of Y~2~O~3~:Eu\@SiO~2~ without X-ray irradiation is as control group (checkered).](thnov10p6758g003){#F3}

![Plot for potential mechanism of ROS generation and radio-luminescence (RL) in Y~2~O~3~:Eu\@SiO~2~.](thnov10p6758g004){#SC1}

![**X-RL image for deep tissue imaging activated by X-ray.** (A) X-RL imaging system consists of a highly sensitive X-RL detector (CCD camera) and X-ray irradiator cabinet is enclosed within a light tight environment. (B) Exposure sensitivity of the X-RL imaging system was assessed by exciting Y~2~O~3~:Eu\@SiO~2~ phantoms under 160 kVp X-rays. (C) The in-vivo calibration curve of X-RL intensity vs. particle concentration using subcutaneously inoculated SKOV3 tumor model.](thnov10p6758g005){#F4}

![**X-ray PDT induced cellular damage in ovarian cells.** Confocal fluorescence microscopy images showing the radiotherapy performance of radioresistant SKOV3 (upper) and radiosensitive CAOV3 (bottom) cancer cells. YO-PRO-1 (green) and propidium iodide (PI) signals (red) denote leakage of the cell and nuclear membranes, respectively. The accumulative Y~2~O~3~:Eu\@SiO~2~ enhanced the ROS generation and increased frequencies of early apoptosis (yellow) and necrosis (white).](thnov10p6758g006){#F5}

![**Survival of the ovarian cells for various tube voltages.** Clonogenic survival assays of SKOV3 and CAOV3 cells treated with radiation alone or with Y~2~O~3~:Eu\@SiO~2~ incubation for 24 h followed by X-ray radiation, respectively.](thnov10p6758g007){#F6}

![**Synergistic effects on tumor growth delay with combined X-ray PDT and fractionated radiation therapy.** (A) The treatment protocol for using hyperfractionated radiation therapy. (B) Radiosensitizing effect of Y~2~O~3~:Eu\@SiO~2~ combined with X-ray irradiation in nude mice bearing SKOV3 tumors. Tumor growths after treatments with PBS, 8 Gy irradiation, Y~2~O~3~:Eu\@SiO~2~ with or without 8 Gy irradiation. Each value represents the mean ± SEM of tumor volume in mm^3^ relative to that measured at the beginning of treatment. (C) Mouse survivals following various treatments. (D) The body weight of mice after various treatments.](thnov10p6758g008){#F7}

![**Validation of hypoxic conditions observed in photoacoustic images *in vivo*.** (A) Oxygen saturation of a representative tumor cross-section profiled by photoacoustic image. (B) Mean deoxygenated hemoglobin of each group after X-ray irradiation. (C) Illustrations of the heterogeneous oxygenated hemoglobin distribution of different treatment groups.](thnov10p6758g009){#F8}

![**RT induces tumor redistribution and vascular damage.** (A) Representative scanner images of immunohistochemistry for Annexin V and caspase-3 in SKOV3 tumors. (B) Representative scanner images of immunohistochemistry for endothelial cells (CD-31) and pericytes (α-SMA) for the different treatment groups after the four days radiation therapy. (C) (D) quantification of CD-31^+^ and α-SMA in SKOV3 tumor. Index values shown in (C) and (D) represent the mean of n≥3 ± SEM.](thnov10p6758g010){#F9}

###### 

Comparison of Y2O3:Eu\@SiO2 concentrations measured using ICP-MS and X-RL in subcutaneously inoculated SKOV3 tumor model

  Sample No.   ICP-MS        Proposed method^a^   Relative error (%)
  ------------ ------------- -------------------- --------------------
  1            1.0158 (mg)   1.2393 (mg)          18%
  2            2.0641 (mg)   1.9695 (mg)          4.8%
  3            2.9323 (mg)   2.6457 (mg)          10.8%
  4            4.2409 (mg)   4.0297 (mg)          5.2%
  5            5.3345 (mg)   5.9025 (mg)          9.6%

a Using radioluminescence property of Y~2~O~3~:Eu\@SiO~2~.
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